Updated Structure of CNBP Repeat Expansions in Patients With Myotonic Dystrophy Type 2 and Its Implication for Standard Diagnostics.

IF 3 3区 医学 Q2 CLINICAL NEUROLOGY Neurology-Genetics Pub Date : 2024-12-18 eCollection Date: 2025-02-01 DOI:10.1212/NXG.0000000000200220
Martin Wendlandt, Hannes Erdmann, Simone Rost, Morghan C Lucas, Kerstin Becker, Stephanie Kleinle, Manuela Timmer, Andrea Bier, Gilbert Wunderlich, Stephan Wenninger, Maggie C Walter, Teresa Neuhann, Benedikt Schoser, Elke Holinski-Feder, Angela Abicht
{"title":"Updated Structure of <i>CNBP</i> Repeat Expansions in Patients With Myotonic Dystrophy Type 2 and Its Implication for Standard Diagnostics.","authors":"Martin Wendlandt, Hannes Erdmann, Simone Rost, Morghan C Lucas, Kerstin Becker, Stephanie Kleinle, Manuela Timmer, Andrea Bier, Gilbert Wunderlich, Stephan Wenninger, Maggie C Walter, Teresa Neuhann, Benedikt Schoser, Elke Holinski-Feder, Angela Abicht","doi":"10.1212/NXG.0000000000200220","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Myotonic dystrophy type 2 (DM2) is a multisystemic repeat disorder caused by the expansion of an unstable CCTG tetranucleotide repeat in the noncoding region of the <i>CNBP</i> gene. Standard diagnostic is based on Southern blot analysis or a unidirectional RP-PCR that amplifies the repeat from the downstream end.</p><p><strong>Methods: </strong>Our study reevaluated 80 patients (cohort 1) with clinical suspicion of DM2 but homozygous negative results using the standard diagnostic repeat-primed PCR (RP-PCR). Reanalysis was performed using a second RP-PCR that amplifies the repeat from the opposite direction. Individual samples were further analyzed by Oxford Nanopore Technology long-read sequencing, Sanger sequencing, and another RP-PCR. In addition, repeat expansions were further characterized in 168 patients with confirmed DM2 (cohort 2).</p><p><strong>Results: </strong>We identified 5 of the 80 patients (cohort 1) with expanded repeats in <i>CNBP</i> and, as such, reclassified them as positive for DM2. The initial false-negative results were attributed to variants within the primer binding site of the standard RP-PCR in one patient and an additional novel (TCTG)<sub>n</sub> repeat downstream to the known (CCTG)<sub>n</sub> repeat in 4 other patients. By analyzing a cohort of 168 patients with confirmed DM2 (cohort 2), we found that the additional (TCTG)<sub>n</sub> repeat is present in at least 84% of patients.</p><p><strong>Discussion: </strong>Our study revealed the presence of an additional repeat (TCTG)<sub>n</sub> in most of the patients living with DM2. Large expansions of this repeat likely hinder sufficient amplification of the disease causing (CCTG)<sub>n</sub> repeat. Because the (TCTG)<sub>n</sub> repeat is likely mosaic in length, (CCTG)<sub>n</sub> repeat expansions are correctly detected in most patients. However, a few patients are at risk of a false-negative result using the standard RP-PCR, which had a false-negative rate of 0.7% (5/674) and a sensitivity of 97.3% in the cohort studied. Based on our findings, we propose (TG)<sub>v</sub>(TCTG)<sub>w</sub>(CCTG)<sub>n</sub>(TCTG')<sub>m</sub> as the updated model for the structure of <i>CNBP</i> repeat expansions and recommend adapting the diagnostic guidelines accordingly. The effect of the (TCTG)<sub>n</sub> repeat on the phenotype remains to be determined but could be key for establishing a phenotype-genotype correlation for DM2 that remained elusive so far.</p>","PeriodicalId":48613,"journal":{"name":"Neurology-Genetics","volume":"11 1","pages":"e200220"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11658809/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology-Genetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/NXG.0000000000200220","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives: Myotonic dystrophy type 2 (DM2) is a multisystemic repeat disorder caused by the expansion of an unstable CCTG tetranucleotide repeat in the noncoding region of the CNBP gene. Standard diagnostic is based on Southern blot analysis or a unidirectional RP-PCR that amplifies the repeat from the downstream end.

Methods: Our study reevaluated 80 patients (cohort 1) with clinical suspicion of DM2 but homozygous negative results using the standard diagnostic repeat-primed PCR (RP-PCR). Reanalysis was performed using a second RP-PCR that amplifies the repeat from the opposite direction. Individual samples were further analyzed by Oxford Nanopore Technology long-read sequencing, Sanger sequencing, and another RP-PCR. In addition, repeat expansions were further characterized in 168 patients with confirmed DM2 (cohort 2).

Results: We identified 5 of the 80 patients (cohort 1) with expanded repeats in CNBP and, as such, reclassified them as positive for DM2. The initial false-negative results were attributed to variants within the primer binding site of the standard RP-PCR in one patient and an additional novel (TCTG)n repeat downstream to the known (CCTG)n repeat in 4 other patients. By analyzing a cohort of 168 patients with confirmed DM2 (cohort 2), we found that the additional (TCTG)n repeat is present in at least 84% of patients.

Discussion: Our study revealed the presence of an additional repeat (TCTG)n in most of the patients living with DM2. Large expansions of this repeat likely hinder sufficient amplification of the disease causing (CCTG)n repeat. Because the (TCTG)n repeat is likely mosaic in length, (CCTG)n repeat expansions are correctly detected in most patients. However, a few patients are at risk of a false-negative result using the standard RP-PCR, which had a false-negative rate of 0.7% (5/674) and a sensitivity of 97.3% in the cohort studied. Based on our findings, we propose (TG)v(TCTG)w(CCTG)n(TCTG')m as the updated model for the structure of CNBP repeat expansions and recommend adapting the diagnostic guidelines accordingly. The effect of the (TCTG)n repeat on the phenotype remains to be determined but could be key for establishing a phenotype-genotype correlation for DM2 that remained elusive so far.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2型肌强直性营养不良患者CNBP重复扩增的更新结构及其对标准诊断的意义。
背景和目的:2型肌强直性营养不良(DM2)是由CNBP基因非编码区不稳定的CCTG四核苷酸重复扩增引起的多系统重复疾病。标准诊断是基于Southern blot分析或单向RP-PCR,从下游端扩增重复序列。方法:本研究采用标准诊断重复引物PCR (RP-PCR)对80例临床怀疑DM2但纯合子阴性的患者(队列1)进行重新评估。使用从相反方向扩增重复序列的第二次RP-PCR进行再分析。通过Oxford Nanopore Technology长读测序、Sanger测序和另一种RP-PCR进一步分析单个样品。此外,在168例确诊DM2患者(队列2)中进一步表征了重复序列扩增。结果:我们在80例患者(队列1)中鉴定出5例CNBP重复序列扩增,因此将其重新分类为DM2阳性。最初的假阴性结果归因于1例患者中标准RP-PCR引物结合位点的变异,以及另外4例患者中已知(CCTG)n重复序列下游的另一个新(TCTG)n重复序列。通过分析168例确诊DM2患者的队列(队列2),我们发现至少84%的患者存在额外的(TCTG)n重复。讨论:我们的研究显示,在大多数患有DM2的患者中存在额外的重复(TCTG)n。该重复序列的大量扩增可能会阻碍致病基因(CCTG)在重复序列中的充分扩增。由于(CCTG)n重复序列在长度上可能是镶嵌的,因此在大多数患者中可以正确检测到(CCTG)n重复序列扩增。然而,少数患者使用标准RP-PCR存在假阴性结果的风险,在研究的队列中,标准RP-PCR的假阴性率为0.7%(5/674),敏感性为97.3%。基于我们的研究结果,我们提出(TG)v(TCTG)w(CCTG)n(TCTG’)m作为CNBP重复扩增结构的更新模型,并建议相应调整诊断指南。(TCTG)n重复序列对表型的影响仍有待确定,但可能是建立DM2表型-基因型相关性的关键,迄今为止仍难以捉摸。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Neurology-Genetics
Neurology-Genetics Medicine-Neurology (clinical)
CiteScore
6.30
自引率
3.20%
发文量
107
审稿时长
15 weeks
期刊介绍: Neurology: Genetics is an online open access journal publishing peer-reviewed reports in the field of neurogenetics. Original articles in all areas of neurogenetics will be published including rare and common genetic variation, genotype-phenotype correlations, outlier phenotypes as a result of mutations in known disease-genes, and genetic variations with a putative link to diseases. This will include studies reporting on genetic disease risk and pharmacogenomics. In addition, Neurology: Genetics will publish results of gene-based clinical trials (viral, ASO, etc.). Genetically engineered model systems are not a primary focus of Neurology: Genetics, but studies using model systems for treatment trials are welcome, including well-powered studies reporting negative results.
期刊最新文献
Review of the Genetic Spectrum of Hereditary Spastic Paraplegias in the Middle East and North Africa Regions. Acid Ceramidase Deficiency: New Insights on SMA-PME Natural History, Biomarkers, and In Cell Enzyme Activity Assay. Association of DMD Gene Variant Classes With Motor Outcomes in a Drug Registration Clinical Trial Setting. "Chocolate Chip Sign" on Susceptibility-Weighted Imaging: A Novel Neuroimaging Biomarker for HTRA1-Related Cerebral Small Vessel Disease. High Prevalence of the Intronic GAA-FGF14 Repeat Expansion in Dutch Patients With Late-Onset Ataxia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1